Repligen to buy BioLife Solutions for USD 1.5 billion in cash-and-stock deal

BioLife Solutions, Inc.
Repligen Corporation

BioLife Solutions, Inc.

BLFS

0.00

Repligen Corporation

RGEN

0.00
  • Repligen agreed to acquire BioLife Solutions for an enterprise value of about USD 1.5 billion, paid 64% in stock, 36% in cash.
  • BioLife holders to receive USD 11.25 in cash plus 0.1442 Repligen shares per share, valued at USD 31.
  • Deal implies a 24% premium to BioLife’s 90-day VWAP through July 21, 2026; closing targeted for Q4 2026.
  • Repligen expects at least USD 20 million of year-one synergies, rising to at least USD 30 million in year two.
  • BioLife posted preliminary Q2 2026 revenue of USD 28.5 million, up 21% year over year.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLife Solutions Inc. published the original content used to generate this news brief on July 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.